Quality of life in patients with rheumatoid arthritis: Which drugs might make a difference?

PharmacoEconomics

Volumn 21, Issue 13, 2003, Pages 927-940

  Blumenauer, Barbara ^a   Cranney, Ann ^a   Clinch, Jennifer ^b   Tugwell, Peter ^a  

^a UNIVERSITY OF OTTAWA   (Canada)

^b UNIVERSITY OF OTTAWA   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AURANOFIN; CYCLOSPORIN; ETANERCEPT; GLUCOCORTICOID; GOLD; INFLIXIMAB; LEFLUNOMIDE; METHOTREXATE; MINOCYCLINE; NONSTEROID ANTIINFLAMMATORY AGENT; PENICILLAMINE; PREDNISOLONE; RECOMBINANT ERYTHROPOIETIN; SALAZOSULFAPYRIDINE; SALICYLIC ACID;

ANXIETY DISORDER; CLINICAL TRIAL; DAILY LIFE ACTIVITY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; EMOTION; HUMAN; MEDICAL LITERATURE; MULTICENTER STUDY; OUTCOMES RESEARCH; PAIN ASSESSMENT; PATIENT MOBILITY; POPULATION RESEARCH; PRIORITY JOURNAL; QUALITY OF LIFE; QUESTIONNAIRE; REVIEW; RHEUMATOID ARTHRITIS; SELF CARE; SOCIOECONOMICS; STATISTICAL ANALYSIS; TREATMENT OUTCOME;

ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; HUMANS; QUALITY OF LIFE;

EID: 0141637479     PISSN: 11707690     EISSN: None     Source Type: Journal    
DOI: 10.2165/00019053-200321130-00002     Document Type: Review

References (28)

1. Krause D, Schleusser B, Herborn G, et al. Response to methotrexate treatment is associated with reduced mortality in patients with severe rheumatoid arthritis. Arthritis Rheum 2000; 43: 14-21
2. Van de Putte LBA, Kroot EJA, van Riel PLCM. Management of refractory rheumatoid arthritis. Rheumatology 1999; 38 Suppl. 2: 32-4
3. Felson DT, Anderson JJ, Boers M, et al. American College of Rheumatology preliminary definition of improvement in rheumatoid arthritis. Arthritis Rheum 1995; 38: 727-35
4. Tuttleman M, Pillemer SR, Tilley BC, et al. A cross sectional assessment of health status instruments in patients with rheumatoid arthritis participating in a clinical trial. J Rheumatol 1997; 24: 1910-5
5. Clinch J, Tugwell P, Wells G, et al. Individualized functional priority approach to the assessment of health related quality of life in rheumatology. J Rheumatol 2001; 28: 445-51
6. Redelmeier DA, Lorig K. Assessing the clinical importance of symptomatic improvements. An illustration in rheumatology. Arch Intern Med 1993; 153: 1337-42
7. Kosinski M, Zhao SZ, Dedhiya S, et al. Determining minimally important changes in generic and disease-specific health-related quality of life questionnaires in clinical trials of rheumatoid arthritis. Arthritis Rheum 2000; 43 (7): 1478-87
8. Fries JF. How may quality of life for rheumatoid arthritis patients be enhanced by current and future treatments? Rheumatology 1999; 38 Suppl. 2: 35-40
9. Buchbinder R, Bombardier C, Yeung M, et al. Which outcome measures should be used in rheumatoid arthritis clinical trials? Arthritis Rheum 1995; 38 (11): 1568-80
10. Scott DL, Garrood T. Quality of life measures use and abuse. Baillieres Best Pract Res Clin Rheumatol 2000; 14 (4): 663-87
11. Bombardier C, Ware J, Russell IJ, et al. Auranofin therapy and quality of lie in patients with rheumatoid arthritis: results of a multicenter trial. Am J Med 1986; 81 (4): 565-78
12. Meenan RF, Anderson JJ, Kazis LE, et al. Outcome assessment in clinical trials: evidence for the sensitivity of a health status measure. Arthritis Rheum 1984; 27 (12): 1344-52
13. Tugwell P, Wells G, Strand V, et al. Clinical improvement as reflected in measures of function and health-related quality of life following treatment with leflunomide compared with methotrexate in patients with rheumatoid arthritis: sensitivity and relative efficiency to detect a treatment effect in a twelve-month, placebo-controlled trial. Arthritis Rheum 2000; 43 (3): 506-14
14. Pouchot J, Guillemin F, Coste J, and the French Quality of Life Rheumatology Group, et al. Validity, reliability and sensitivity to change of a French version of the arthritis impact measurement scales2 (AIMS2) in patients with rheumatoid arthritis treated with methotrexate. J Rheumatol 1996; 23: 52-60
15. Tugwell P, Bombardier C, Buchanan WW. Methotrexate in rheumatoid arthritis: impact on quality of life assessed by traditional standard-item and individualized patient preference health status questionnaires. Arch Intern Med 1990; 150: 59-62
16. Tugwell P, Bombardier C, Gent M, et al. Low-dose cyclosporin versus placebo in patients with rheumatoid arthritis. Lancet 1990; 335: 1051-5
17. Tugwell P, Pincus T, Yocum D, et al. Combination therapy with cyclosporine and methotrexate in severe rheumatoid arthritis. N Engl J Med 1995; 333: 137-41
18. Tilley BC, Alarcon GS, Heyse SP, for the MIRA Trial Group, et al. Minocycline in rheumatoid arthritis. A 48-week, double blind, placebo-controlled trial. Ann Intern Med 1995; 122: 81-9
19. Mathias SD, Colwell HH, Miller DP, et al. Health-related quality of life and functional status of patients with rheumatoid arthritis randomly assigned to receive etanercept or placebo. Clin Ther 2000; 22: 128-39
20. Smolen JS, Kalden JR, Scott DL, et al. Efficacy and safety of leflunomide compared to placebo and sulphasalazine in active rheumatoid arthritis: a double-blind, randomised, multicentre trial. European Leflunomide Study Group. Lancet 1999; 353 (9149): 259-66
21. Strand V, Tugwell P, Bombardier C, et al. Function and health-related quality of life: results from a randomized controlled trial of leflunomide versus methotrexate or placebo in patients with active rheumatoid arthritis. Arthritis Rheum 1999; 42 (9): 1870-8
22. Scott DL. Leflunomide improves quality of life in rheumatoid arthritis. Scand J Rheumatol 1999; 28 Suppl. 112: 23-9
23. Bombardier C, Buchbinder R, Tugwell P. Efficacy of cyclosporin A in rheumatoid arthritis: long-term follow-up data and the effect on quality of life. Scand J Rheumatol 1992; 21 Suppl. 95: 29-33
24. Kirwan JR, The Arthritis and Rheumatism Council Low-Dose Glucocorticoid Study Group. The effect of glucocorticoids on joint destruction in rheumatoid arthritis. N Engl J Med 1995; 333: 142-6
25. Lipsky PE, Van Der Heijde DMFM, St Clair EW, for the Anti-Tumour Necrosis Factor Trial In Rheumatoid Arthritis With Concomitant Therapy Study Group, et al. Infliximab and methotrexate in the treatment of rheumatoid arthritis. N Engl J Med 2000; 343: 1594-602
26. Peeters HRM, Jongen-Lavrencic M, Bakker CH, et al. Recombinant human erythropoietin improves health-related quality of life in patients with rheumatoid arthritis and anaemia of chronic disease; utility measures correlate strongly with disease activity measures. Rheumatol Int 1999; 18: 201-6
27. Murphy EA, Bell AL, Wojtulewski J, et al. Study of erythropoietin in treatment of anemia in patients with rheumatoid arthritis. BMJ 1994; 309: 1337-8
28. Pincus T, Olsen NJ, Russell IJ, et al. Multicenter study of recombinant human erythropoietin in correction of anemia in rheumatoid arthritis. Am J Med 1990; 89 (2): 161-8